Litfulo improved pigmentation for adults, teens with nonsegmental vitiligo: Topline data

Once-daily ritlecitinib demonstrated clinically meaningful improvements in nonsegmental vitiligo on the face and body in adults and adolescents 12 years and older, according to topline data from two phase 3 studies. The trials, conducted within the TRANQUILLO clinical development program, met their coprimary endpoints in the United States and their primary and secondary endpoints in other

Raccontata dahealio.com